tiprankstipranks
Trending News
More News >
Advertisement
Advertisement
Longeveron: Buy Rating Backed by Promising Clinical Developments and Strategic Financial Outlook
PremiumRatingsLongeveron: Buy Rating Backed by Promising Clinical Developments and Strategic Financial Outlook
3M ago
Longeveron price target lowered to $3 from $10 at Roth Capital
Premium
The Fly
Longeveron price target lowered to $3 from $10 at Roth Capital
3M ago
Longeveron Inc. Faces Regulatory and Manufacturing Challenges Threatening Financial Stability
Premium
Company Announcements
Longeveron Inc. Faces Regulatory and Manufacturing Challenges Threatening Financial Stability
3M ago
Longeveron files to sell 3.85M shares of Class A common stock
PremiumThe FlyLongeveron files to sell 3.85M shares of Class A common stock
3M ago
Longeveron licenses patent for stem cell technology from University of Miami
Premium
The Fly
Longeveron licenses patent for stem cell technology from University of Miami
3M ago
Longeveron Gains FDA Approval for Laromestrocel Trial
Premium
Company Announcements
Longeveron Gains FDA Approval for Laromestrocel Trial
4M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100